MGMT and glioblastoma: This study involved a retrospective analysis of medical records of patients diagnosed with GBM at the Santiago de Compostela University Clinical Hospital in Santiago de Compostela, Spain, during the period from January 2019 to November 2022 and aimed to compare the methylation results of MGMT using PSQ with the treatment response (TR) and disease-specific survival (DSS) of these patients.